Back to Research Home
IBRXImmunitybio Inc
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · Mid
$8.22−1.08%
As of 23 Oct 2026Mkt cap $8.4B
Stage 13
WAIT
Fundamentals
—/75
Technical
5.9/15
Independent
—/90
GCAE viewtechnical state requires waiting rather than entering now
Price
- 1M
- −4.9%
- 3M
- +17.6%
- 6M
- +10.5%
- 1Y
- +248.3%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- —
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- —
- FCF yield
- —
Quality
- ROIC
- —
- Operating margin
- -2334.2%
- FCF margin
- -272.6%
- Current ratio
- 5.1x
Growth
- Revenue growth
- +668.3%Latest FY YoY
- Revenue CAGR
- +231.9%
- EPS CAGR
- —
- FCF CAGR
- —
Capital
- Share-count trend
- +34.5%3Y annualised
- Net cash
- $46M
Annual trend
- CAGR 2021–2025
- +231.9%
- Latest · 2025
- $0B
- YoY
- +668.3%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- FUNDAMENTAL GATE FAIL
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
technical state requires waiting rather than entering now
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-11-03
More details & evidence
Production decision
- Stage 13
- WAIT
- Technical state
- extended
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded